JP2012509340A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012509340A5 JP2012509340A5 JP2011537586A JP2011537586A JP2012509340A5 JP 2012509340 A5 JP2012509340 A5 JP 2012509340A5 JP 2011537586 A JP2011537586 A JP 2011537586A JP 2011537586 A JP2011537586 A JP 2011537586A JP 2012509340 A5 JP2012509340 A5 JP 2012509340A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- vaccine
- nos
- optimized
- polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960005486 vaccine Drugs 0.000 claims description 69
- 229920001184 polypeptide Polymers 0.000 claims description 42
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 42
- 230000003612 virological effect Effects 0.000 claims description 29
- 241000701161 unidentified adenovirus Species 0.000 claims description 17
- 108010067390 Viral Proteins Proteins 0.000 claims description 16
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 11
- 208000031886 HIV Infections Diseases 0.000 claims description 10
- 241000700605 Viruses Species 0.000 claims description 8
- 208000036142 Viral infection Diseases 0.000 claims description 7
- 239000003085 diluting agent Substances 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000013598 vector Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 6
- 241000205701 Human adenovirus 26 Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000701124 Human adenovirus 35 Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 230000002194 synthesizing effect Effects 0.000 claims description 2
- 241001183012 Modified Vaccinia Ankara virus Species 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 241000282412 Homo Species 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 description 11
- 102000039446 nucleic acids Human genes 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 241001430294 unidentified retrovirus Species 0.000 description 8
- 230000024932 T cell mediated immunity Effects 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 6
- 241000712891 Arenavirus Species 0.000 description 4
- 241000711573 Coronaviridae Species 0.000 description 4
- 241000711950 Filoviridae Species 0.000 description 4
- 241000710831 Flavivirus Species 0.000 description 4
- 241000713112 Orthobunyavirus Species 0.000 description 4
- 241001631646 Papillomaviridae Species 0.000 description 4
- 241000709664 Picornaviridae Species 0.000 description 4
- 241001505332 Polyomavirus sp. Species 0.000 description 4
- 241000125945 Protoparvovirus Species 0.000 description 4
- 241000702263 Reovirus sp. Species 0.000 description 4
- 244000309743 astrovirus Species 0.000 description 4
- 241001529453 unidentified herpesvirus Species 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11570308P | 2008-11-18 | 2008-11-18 | |
| US61/115,703 | 2008-11-18 | ||
| US15218409P | 2009-02-12 | 2009-02-12 | |
| US61/152,184 | 2009-02-12 | ||
| US24818809P | 2009-10-02 | 2009-10-02 | |
| US61/248,188 | 2009-10-02 | ||
| PCT/US2009/064999 WO2010059732A1 (en) | 2008-11-18 | 2009-11-18 | Antiviral vaccines with improved cellular immunogenicity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015021128A Division JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012509340A JP2012509340A (ja) | 2012-04-19 |
| JP2012509340A5 true JP2012509340A5 (enExample) | 2013-12-19 |
| JP5694945B2 JP5694945B2 (ja) | 2015-04-01 |
Family
ID=42198483
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011537586A Expired - Fee Related JP5694945B2 (ja) | 2008-11-18 | 2009-11-18 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2015021128A Expired - Fee Related JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2016198037A Expired - Fee Related JP6224197B2 (ja) | 2008-11-18 | 2016-10-06 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2017193941A Expired - Fee Related JP6368416B2 (ja) | 2008-11-18 | 2017-10-04 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015021128A Expired - Fee Related JP6023233B2 (ja) | 2008-11-18 | 2015-02-05 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2016198037A Expired - Fee Related JP6224197B2 (ja) | 2008-11-18 | 2016-10-06 | 細胞性免疫原性が向上した抗ウイルスワクチン |
| JP2017193941A Expired - Fee Related JP6368416B2 (ja) | 2008-11-18 | 2017-10-04 | 細胞性免疫原性が向上した抗ウイルスワクチン |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US9017691B2 (enExample) |
| EP (2) | EP3470437A1 (enExample) |
| JP (4) | JP5694945B2 (enExample) |
| CN (1) | CN102282175B (enExample) |
| AP (1) | AP3719A (enExample) |
| AU (1) | AU2009316629B2 (enExample) |
| BR (2) | BRPI0921588B1 (enExample) |
| CY (1) | CY1121215T1 (enExample) |
| DK (1) | DK2358757T3 (enExample) |
| ES (1) | ES2699685T3 (enExample) |
| HR (1) | HRP20181776T1 (enExample) |
| HU (1) | HUE042397T2 (enExample) |
| IL (2) | IL212984A (enExample) |
| LT (1) | LT2358757T (enExample) |
| NZ (2) | NZ593598A (enExample) |
| PL (1) | PL2358757T3 (enExample) |
| PT (1) | PT2358757T (enExample) |
| SG (1) | SG10201408784SA (enExample) |
| SI (1) | SI2358757T1 (enExample) |
| SM (1) | SMT201800631T1 (enExample) |
| WO (1) | WO2010059732A1 (enExample) |
| ZA (2) | ZA201104538B (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3227814B2 (ja) | 1992-07-29 | 2001-11-12 | 三菱マテリアル株式会社 | スクラッププレス装置 |
| SMT202000101T1 (it) | 2008-10-10 | 2020-03-13 | Childrens Medical Center | Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente |
| NZ593598A (en) | 2008-11-18 | 2013-02-22 | Beth Israel Hospital | Optimized antiviral vaccines with improved cellular immunogenicity |
| EP2620446A1 (en) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogens for HIV vaccination |
| ES3040856T3 (en) | 2012-11-16 | 2025-11-05 | Beth Israel Deaconess Medical Ct Inc | Recombinant adenoviruses and use thereof |
| AP2015008634A0 (en) * | 2013-01-07 | 2015-07-31 | Beth Israel Hospital | Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same |
| EP3052132B1 (en) | 2013-09-30 | 2020-07-29 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| EP3052518B1 (en) | 2013-10-04 | 2020-01-08 | Beth Israel Deaconess Medical Center, Inc. | Stabilized human immunodeficiency virus (hiv) clade c envelope (env) trimer vaccines and methods of using same |
| JP6649252B2 (ja) * | 2013-10-07 | 2020-02-19 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | アジュバントとしてのインターロイキン−３３を有するワクチン |
| JP6769869B2 (ja) * | 2013-10-16 | 2020-10-14 | ニユー・イングランド・バイオレイブス・インコーポレイテツド | 強化された特性を有する逆転写酵素 |
| EP3110953A1 (en) * | 2014-02-28 | 2017-01-04 | Janssen Vaccines & Prevention B.V. | Replicating recombinant adenovirus vectors, compositions, and methods of use thereof |
| HUE053585T2 (hu) | 2014-09-26 | 2021-07-28 | Beth Israel Deaconess Medical Ct Inc | Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására |
| MA40783A (fr) * | 2014-10-03 | 2017-08-08 | Los Alamos Nat Security Llc | Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population |
| US10306895B2 (en) * | 2014-10-27 | 2019-06-04 | Academia Sinica | Plant defense signaling peptides and applications thereof |
| WO2016196471A1 (en) | 2015-06-02 | 2016-12-08 | Cooper Human Systems Llc | Methods and compositions for treatment of hiv infection |
| US10542961B2 (en) | 2015-06-15 | 2020-01-28 | The Research Foundation For The State University Of New York | System and method for infrasonic cardiac monitoring |
| US10758609B2 (en) * | 2015-09-25 | 2020-09-01 | University Of Florida Research Foundation, Inc. | Cross-reactive T-cell epitopes of HIV, SIV, and FIV for vaccines in humans and cats |
| PL3390430T3 (pl) | 2015-12-15 | 2020-03-31 | Janssen Vaccines & Prevention B.V. | Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania |
| KR102389489B1 (ko) | 2016-06-16 | 2022-04-22 | 얀센 백신스 앤드 프리벤션 비.브이. | Hiv 백신 제형 |
| US10307477B2 (en) | 2016-09-02 | 2019-06-04 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| SG10202001956UA (en) | 2016-09-15 | 2020-04-29 | Janssen Vaccines & Prevention Bv | Trimer stabilizing hiv envelope protein mutations |
| US11230572B2 (en) | 2016-10-17 | 2022-01-25 | Beth Israel Deaconess Medical Center, Inc. | Signature-based human immunodeficiency virus (HIV) envelope (Env) trimer vaccines and methods of using the same |
| BR112019026126A2 (pt) * | 2017-06-15 | 2020-06-30 | Janssen Vaccines & Prevention B.V. | vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos |
| EP3655032A1 (en) | 2017-07-19 | 2020-05-27 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations |
| US20190022212A1 (en) | 2017-07-21 | 2019-01-24 | Beth Israel Deaconess Medical Center, Inc. | Methods for safe induction of cross-clade immunity against human immunodeficiency virus infection in human |
| US20190083620A1 (en) | 2017-09-18 | 2019-03-21 | Janssen Vaccines & Prevention B.V. | Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment |
| EP3723771A4 (en) | 2017-12-11 | 2022-04-06 | Beth Israel Deaconess Medical Center, Inc. | Recombinant adenoviruses and uses thereof |
| WO2019226829A1 (en) | 2018-05-22 | 2019-11-28 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (hiv) |
| AU2019345942A1 (en) | 2018-09-25 | 2021-03-18 | Janssen Vaccines & Prevention B.V. | Method of inducing an immune response against human immunodeficiency virus by co-localized administration of vaccine components |
| US12459989B2 (en) | 2018-11-21 | 2025-11-04 | Beth Israel Deaconess Medical Center, Inc. | Antibody therapies for human immunodeficiency virus (HIV) |
| KR20220011685A (ko) | 2019-05-22 | 2022-01-28 | 길리애드 사이언시즈, 인코포레이티드 | Tlr7 조절 화합물과 hiv 백신의 조합 |
| TW202110476A (zh) | 2019-05-22 | 2021-03-16 | 荷蘭商傑森疫苗防護公司 | 於接受抗反轉錄病毒治療之個體中誘發抗人類免疫缺乏病毒感染之免疫反應的方法 |
| AU2020315598B2 (en) | 2019-07-16 | 2024-12-12 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| EP4058058A1 (en) | 2019-11-14 | 2022-09-21 | Aelix Therapeutics S.L. | Dosage regimens for vaccines |
| WO2021155323A1 (en) | 2020-01-31 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
| US12558415B2 (en) | 2020-04-14 | 2026-02-24 | The Regents Of The University Of California | Broad-spectrum multi-antigen pan-coronavirus vaccine |
| WO2021211749A1 (en) * | 2020-04-14 | 2021-10-21 | The Regents Of The University Of California | Multi-epitope pan-coronavirus vaccine compositions |
| WO2021228816A1 (en) | 2020-05-12 | 2021-11-18 | Janssen Vaccines & Prevention B.V. | Administration of homologous adenoviral vectors |
| US20220118081A1 (en) | 2020-10-20 | 2022-04-21 | Janssen Vaccines & Prevention B.V. | HIV vaccine regimens |
| EP4277652A1 (en) * | 2021-01-14 | 2023-11-22 | Gilead Sciences, Inc. | Hiv vaccines and methods of using |
| CA3211197A1 (en) | 2021-02-23 | 2022-09-01 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutation |
| WO2023123375A1 (zh) * | 2021-12-31 | 2023-07-06 | 京东方科技集团股份有限公司 | 一种hiv假病毒颗粒及其制备方法 |
| WO2023156505A1 (en) | 2022-02-17 | 2023-08-24 | Janssen Vaccines & Prevention B.V. | Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l |
| WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
| WO2024167803A2 (en) * | 2023-02-07 | 2024-08-15 | Merck Sharp & Dohme Llc | Adjuvant formulations including low viscosity chitosan or chitosan derivatives |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US5298416A (en) | 1989-01-18 | 1994-03-29 | British Technology Group Ltd. | Attenuated polioviruses |
| WO1992015672A1 (en) | 1991-03-07 | 1992-09-17 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US6479258B1 (en) | 1995-12-07 | 2002-11-12 | Diversa Corporation | Non-stochastic generation of genetic vaccines |
| US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| US20050232900A1 (en) | 1999-05-18 | 2005-10-20 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
| AU2001294562B2 (en) * | 2000-09-15 | 2007-05-24 | Merck & Co., Inc. | Enhanced First Generation Adenovirus Vaccines Expressing Codon Optimized HIV1-Gag, Pol, Nef and Modifications |
| US20040101957A1 (en) * | 2001-09-14 | 2004-05-27 | Emini Emilio A. | Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol.nef and modifications |
| AU2002363436A1 (en) | 2001-11-07 | 2003-05-19 | Duke University | Polyvalent immunogen of hiv |
| US7172761B2 (en) | 2001-11-07 | 2007-02-06 | Duke University | Polyvalent immunogen |
| US7195768B2 (en) | 2001-11-07 | 2007-03-27 | Duke University | Polyvalent immunogen |
| WO2003046137A2 (en) | 2001-11-27 | 2003-06-05 | Duke University | Hiv envelope v3-ccr5 binding site immunogen |
| JP4495588B2 (ja) | 2002-04-25 | 2010-07-07 | クルセル ホランド ベー ヴェー | 安定なアデノウイルスベクターおよびその増殖方法 |
| US20080153083A1 (en) | 2003-10-23 | 2008-06-26 | Crucell Holland B.V. | Settings for recombinant adenoviral-based vaccines |
| WO2004037294A2 (en) | 2002-10-23 | 2004-05-06 | Crucell Holland B.V. | New settings for recombinant adenoviral-based vaccines |
| US20050221493A1 (en) | 2002-12-04 | 2005-10-06 | Crucell Holland B.V. | Recombinant virus production for the manufacturing of vaccines |
| BRPI0414443A (pt) | 2003-09-17 | 2006-11-21 | Univ Duke | imunógenos consensuais/ancestrais |
| WO2005052119A2 (en) | 2003-11-19 | 2005-06-09 | Beth Israel Deaconess Medical Center | Adjuvants of immune response |
| BRPI0516048A (pt) | 2004-10-13 | 2008-08-19 | Crucell Holland B V E Beth Isr | batelada de um adenovìrus recombinante defectivo em replicação baseado em um sorotipo do subgrupo c |
| NZ581306A (en) | 2004-11-16 | 2011-03-31 | Crucell Holland Bv | Multivalent vaccines comprising recombinant viral vectors |
| US7951377B2 (en) | 2005-08-23 | 2011-05-31 | Los Alamos National Security, Llc | Mosaic clade M human immunodeficiency virus type 1 (HIV-1) envelope immunogens |
| AU2006283101B2 (en) | 2005-08-23 | 2013-03-07 | Beth Israel Deaconess Medical Center | Polyvalent vaccine |
| US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
| US20080279879A1 (en) | 2006-11-17 | 2008-11-13 | New York University | INDUCTION OF BROADLY REACTIVE NEUTRALIZING ANTIBODIES BY FOCUSING THE IMMUNE RESPONSE ON V3 EPITOPES OF THE HIV-1 gp120 ENVELOPE |
| WO2008118470A2 (en) | 2007-03-27 | 2008-10-02 | The Regents Of The University Of California | Acute transmitted hiv envelope signatures |
| WO2010042817A1 (en) * | 2008-10-10 | 2010-04-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Use of hiv mosaic envelope proteins to optimize t-cell responses against hiv envelope |
| NZ593598A (en) | 2008-11-18 | 2013-02-22 | Beth Israel Hospital | Optimized antiviral vaccines with improved cellular immunogenicity |
| WO2010096561A1 (en) | 2009-02-18 | 2010-08-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synthetic hiv/siv gag proteins and uses thereof |
| US9017961B2 (en) | 2012-03-05 | 2015-04-28 | E.I. Du Pont De Nemours And Company | Recombinant bacteria comprising novel sucrose transporters |
-
2009
- 2009-11-18 NZ NZ593598A patent/NZ593598A/xx not_active IP Right Cessation
- 2009-11-18 BR BRPI0921588-3A patent/BRPI0921588B1/pt not_active IP Right Cessation
- 2009-11-18 BR BR122021004758-8A patent/BR122021004758B1/pt active IP Right Grant
- 2009-11-18 AU AU2009316629A patent/AU2009316629B2/en not_active Ceased
- 2009-11-18 EP EP18191558.8A patent/EP3470437A1/en not_active Withdrawn
- 2009-11-18 WO PCT/US2009/064999 patent/WO2010059732A1/en not_active Ceased
- 2009-11-18 DK DK09828172.8T patent/DK2358757T3/da active
- 2009-11-18 JP JP2011537586A patent/JP5694945B2/ja not_active Expired - Fee Related
- 2009-11-18 PT PT09828172T patent/PT2358757T/pt unknown
- 2009-11-18 SM SM20180631T patent/SMT201800631T1/it unknown
- 2009-11-18 SG SG10201408784SA patent/SG10201408784SA/en unknown
- 2009-11-18 ES ES09828172T patent/ES2699685T3/es active Active
- 2009-11-18 HU HUE09828172A patent/HUE042397T2/hu unknown
- 2009-11-18 EP EP09828172.8A patent/EP2358757B1/en active Active
- 2009-11-18 CN CN200980154787.4A patent/CN102282175B/zh not_active Expired - Fee Related
- 2009-11-18 NZ NZ60250409A patent/NZ602504A/en not_active IP Right Cessation
- 2009-11-18 HR HRP20181776TT patent/HRP20181776T1/hr unknown
- 2009-11-18 SI SI200931885T patent/SI2358757T1/sl unknown
- 2009-11-18 PL PL09828172T patent/PL2358757T3/pl unknown
- 2009-11-18 AP AP2011005767A patent/AP3719A/en active
- 2009-11-18 US US13/130,018 patent/US9017691B2/en active Active
- 2009-11-18 LT LTEP09828172.8T patent/LT2358757T/lt unknown
-
2011
- 2011-05-18 IL IL212984A patent/IL212984A/en active IP Right Grant
- 2011-06-20 ZA ZA2011/04538A patent/ZA201104538B/en unknown
-
2012
- 2012-07-04 ZA ZA2012/04999A patent/ZA201204999B/en unknown
-
2015
- 2015-02-05 JP JP2015021128A patent/JP6023233B2/ja not_active Expired - Fee Related
- 2015-02-26 US US14/632,869 patent/US9670253B2/en active Active
-
2016
- 2016-02-07 IL IL243991A patent/IL243991B/en active IP Right Grant
- 2016-10-06 JP JP2016198037A patent/JP6224197B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-17 US US15/489,220 patent/US10426831B2/en not_active Expired - Fee Related
- 2017-10-04 JP JP2017193941A patent/JP6368416B2/ja not_active Expired - Fee Related
-
2018
- 2018-12-10 CY CY20181101309T patent/CY1121215T1/el unknown
-
2019
- 2019-06-14 US US16/441,703 patent/US10772952B2/en not_active Expired - Fee Related
-
2020
- 2020-09-10 US US16/948,257 patent/US11331386B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6368416B2 (ja) | 細胞性免疫原性が向上した抗ウイルスワクチン | |
| US8137931B2 (en) | Fusion proteins of HIV regulatory/accessory proteins | |
| CN105263506B (zh) | 稳定的人免疫缺陷病毒(HIV)包膜(EnV)三聚体疫苗及其使用方法 | |
| JP2019526580A5 (enExample) | ||
| JP2013507107A5 (enExample) | ||
| JP2010539901A5 (enExample) | ||
| MX2012002531A (es) | Generacion de una respuesta amplia de celulas t en humanos contra el virus de inmunodeficiencia humana (vih). | |
| WO2012162428A1 (en) | Prime-boost vaccination for viral infection | |
| Zubair et al. | Clinical trials and recent progress in HIV vaccine development | |
| WO2007137591A3 (en) | Hiv vaccine | |
| WO2005052165A1 (ja) | 抗ヒト免疫不全ウイルス感染防御用キメラ５型/１１型もしくは３５型アデノウイルスベクター | |
| CN103966259B (zh) | 一种基于J亚群禽白血病病毒gag基因保守序列的siRNA重组干扰载体及其制备方法和应用 | |
| CN102258779A (zh) | 四种及四种以上hiv载体基因疫苗序贯及重复应用 | |
| Villefroy et al. | SIV escape mutants in rhesus macaques vaccinated with NEF-derived lipopeptides and challenged with pathogenic SIVmac251 | |
| CN121360246A (zh) | Klf7及其d264n突变型相关基因/蛋白在hiv病毒感染疾病中的应用 |